An Open Label Safety Study of Tipranavir Co-administered With Low-dose Ritonavir in Patients With Advanced HIV-1 Infection and Limited Treatment Options.
The purpose of this Open Label Safety Study is to provide early access to and assess the safety and tolerability of tipranavir co-administered with low-dose ritonavir (500 mgTPV/200 mg RTV BID) in HIV-1 infected patients which are triple antiretroviral class experienced with at least two previous PI-containing regimens.
|Study Type:||Expanded Access What is Expanded Access?|
|Official Title:||Open Label Safety Study o Tipranavir Co-administered With Low-dose Ritonavir (TPV/r) in Patients With Advanced HIV-1 Infection and Limited Treatment Options.|
Show 215 Study Locations
|Study Chair:||Boehringer Ingelheim||Boehringer Ingelheim Pharmaceuticals|